We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

By LabMedica International staff writers
Posted on 09 Apr 2025

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. More...

This resistance is partially due to the activation and selection of cancer stem cells (CSCs) that repair and rebuild the tumor after chemotherapy damage. New findings from a Phase 3 trial, published in the journal npj Precision Oncology, reveal that a test for cancer stem cells can help identify more effective treatments and improve outcomes for patients with platinum-resistant ovarian cancer (those who experience recurrence within six months after receiving platinum-based chemotherapy).

The ChemoID platform, developed by researchers at the University of Cincinnati (Cincinnati, OH, USA), works by testing cancer stem cells found in individual patients' tumors against specific anticancer drugs to determine the most effective treatment options. The platform operates under the premise that by evaluating both tumor cells and cancer stem cells for chemosensitivity, one can target and eliminate CSCs that could otherwise repopulate the tumor. In the trial, 81 patients with platinum-resistant ovarian cancer were randomly assigned to have their chemotherapy treatment chosen using the ChemoID platform or based on the physician's standard methods. Physicians typically select treatments based on approved therapies, their previous experiences, past treatments the patient has undergone, and the side effects or toxicity that the patient has previously experienced.

The primary outcome measured was the patients’ objective response rate (ORR), which refers to the percentage of patients in each group who achieved either a partial or complete response to the treatment within a designated period. In addition, progression-free survival (PFS)—the duration of time a patient lives without the cancer worsening during and after treatment—and the duration of the response were measured. Results showed that patients who were treated using the ChemoID assay had significantly better clinical and statistical outcomes compared to those who received the physician’s choice of therapy. The ORR for patients in the ChemoID group was 50%, while only 5% of patients in the physician-choice group responded positively.

Median PFS for patients in the ChemoID group was 11 months, compared to only three months in the physician-choice group. Furthermore, patients in the ChemoID group had a median duration of response of eight months, whereas those in the physician-choice group experienced just five-and-a-half months. These improved response rates could potentially reduce healthcare costs associated with ineffective therapies and unnecessary toxicity, according to researchers.

The findings from this study suggest that using assay-guided treatment approaches could reduce financial toxicity for ovarian cancer patients, particularly those with platinum-resistant disease who often struggle with treatment decisions. Future studies are needed to further validate the ChemoID platform and explore how it works with different molecular subgroups, such as patients with BRCA mutations. Additionally, the testing of emerging biologic therapies will help refine the best uses for this test.


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
Specimen Radiography System
TrueView 200 Pro
New
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The patented biosensor measures enzymatic activity associated with inflammatory disease (Photo courtesy of Hawkeye Bio)

Non-Invasive and Radiation-Free Diagnostic Identifies Early-Stage Lung Cancer Across All Subtypes

Lung cancer remains the leading cause of cancer-related deaths, with nearly 125,000 deaths and 227,000 new cases estimated in the U.S. for 2025. Despite evidence showing that early detection significantly... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.